{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:29:36Z","timestamp":1784366976958,"version":"3.55.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>The aim of this study was to investigate frequencies, types, and signals of adverse drug events (ADEs) associated with sodium zirconium cyclosilicate (SZC) used for the treatment of hyperkalemia, in order to inform clinicians of possible safety concerns linked with SZC in real-life usage. ADE reports associated with SZC were collected from both the FAERS and VigiAccess databases. Data extraction from FAERS was performed using OpenVigil 2.1, covering reports from the first quarter of 2004 through the third quarter of 2024. The VigiAccess database was retrieved for reports up to February 5, 2025. The ADEs were standardized and classified by using the preferred term (PT) and the system organ class (SOC) of the Medical Dictionary for Regulatory Activities (MedDRA) (Version 27.0). The reporting odds ratio (ROR) method and the proportional reporting ratio (PRR) method were used to screen positive signals and analyze the characteristics of ADE signals. In this study, 1384 and 1518 ADE reports related to SZC were obtained from the FAERS database and the VigiAccess database, respectively. At the SOC level, the ADEs retrieved in the two databases involved 26 SOCs, and the top 3 SOCs in terms of the number of reported cases were general disorders and administration site conditions, gastrointestinal disorders, and investigations. At the PT level, among the top 30 PTs in terms of the number of reported cases in the two databases, death, cardiac failure, weight increased, blood pressure increased, cardiac failure congestive, cerebrovascular accident, myocardial infarction, pneumonia, dizziness, dysphagia, and dyspnoea were the ADEs with higher number of reported cases not included in the drug instructions. A total of 41 positive signals were obtained after signal screening in FAERS database. Among them, the top 3 PTs in terms of signal strength were blood potassium abnormal (ROR = 180.224[119.925, 270.842]), blood potassium increased (ROR = 98.789[78.835, 123.792]), blood sodium increased (ROR = 35.248[14.624, 84.961]). Signals of cardiac disorders such as cardiac failure chronic, cardiac failure and cardiac failure congestive, signals of gastrointestinal disorders such as ileus and intestinal perforation, and signals of blood sodium increased and hypernatraemia are positive signals that deserve special attention. In this study, the common ADEs associated with SZC were confirmed, and several intriguing novel signals not included in the drug instructions were discovered, which would provide more safety reference data for the clinical use of SZC.<\/jats:p>","DOI":"10.1371\/journal.pone.0333692","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:37:26Z","timestamp":1760117846000},"page":"e0333692","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world study of adverse events associated with sodium zirconium cyclosilicate based on FDA adverse event reporting system and VigiAccess database"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1474-9952","authenticated-orcid":true,"given":"Xiaona","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"pone.0333692.ref001","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijcard.2017.07.035","article-title":"Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system","volume":"245","author":"E Nilsson","year":"2017","journal-title":"Int J Cardiol."},{"issue":"4","key":"pone.0333692.ref002","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/MAJ.0b013e3181836ac7","article-title":"Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: Risk factors analysis","volume":"336","author":"S Maddirala","year":"2008","journal-title":"Am J Med Sci."},{"issue":"10","key":"pone.0333692.ref003","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1358\/dot.2018.54.10.2872504","article-title":"Sodium zirconium cyclosilicate: A new potassium binder for the treatment of hyperkalemia","volume":"54","author":"A Cases","year":"2018","journal-title":"Drugs Today (Barc)."},{"issue":"1","key":"pone.0333692.ref004","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/14656566.2020.1810234","article-title":"An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia","volume":"22","author":"C Takkar","year":"2021","journal-title":"Expert Opin Pharmacother."},{"issue":"3","key":"pone.0333692.ref005","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","article-title":"Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"4","author":"GMC Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"7","key":"pone.0333692.ref006","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005428","article-title":"Hyperkalemia after initiating renin-angiotensin system blockade: The stockholm creatinine measurements (SCREAM) project","volume":"6","author":"G Bandak","year":"2017","journal-title":"J Am Heart Assoc."},{"issue":"9","key":"pone.0333692.ref007","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/17512433.2021.1932460","article-title":"Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent","volume":"14","author":"A Rastogi","year":"2021","journal-title":"Expert Rev Clin Pharmacol."},{"issue":"12","key":"pone.0333692.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"F Stavros","year":"2014","journal-title":"PLoS One."},{"issue":"3","key":"pone.0333692.ref009","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1177\/08971900231176462","article-title":"Comparison of sodium zirconium cyclosilicate to sodium polystyrene sulfonate in the inpatient management of acute hyperkalemia","volume":"37","author":"O Joyce","year":"2024","journal-title":"J Pharm Pract."},{"key":"pone.0333692.ref010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejim.2023.08.022","article-title":"Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis","volume":"119","author":"S Paolillo","year":"2024","journal-title":"Eur J Intern Med."},{"issue":"6","key":"pone.0333692.ref011","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/nep.14281","article-title":"Consensus statement on the management of hyperkalaemia-An Asia-Pacific perspective","volume":"29","author":"DYH Yap","year":"2024","journal-title":"Nephrology (Carlton)."},{"issue":"1","key":"pone.0333692.ref012","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12882-022-02903-7","article-title":"Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden","volume":"23","author":"K Kim","year":"2022","journal-title":"BMC Nephrol."},{"issue":"6","key":"pone.0333692.ref013","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2215\/CJN.12651018","article-title":"Sodium zirconium cyclosilicate among individuals with hyperkalemia: A 12-month phase 3 study","volume":"14","author":"BS Spinowitz","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"pone.0333692.ref014","first-page":"54","article-title":"Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: The randomized, placebo-controlled HARMONIZE-Global study","volume":"7","author":"F Zannad","year":"2020","journal-title":"ESC Heart Fail."},{"issue":"6","key":"pone.0333692.ref015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/acem.13954","article-title":"Emergency potassium normalization treatment including sodium zirconium cyclosilicate: A phase II, randomized, double-blind, placebo-controlled study (ENERGIZE)","volume":"27","author":"WF Peacock","year":"2020","journal-title":"Acad Emerg Med."},{"issue":"9","key":"pone.0333692.ref016","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.clinthera.2024.07.004","article-title":"HARMONIZE Asia: A phase III randomized study to investigate the efficacy and safety of sodium zirconium cyclosilicate in patients with hyperkalemia in China","volume":"46","author":"X Liang","year":"2024","journal-title":"Clin Ther."},{"issue":"8","key":"pone.0333692.ref017","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/bcp.15673","article-title":"A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database","volume":"90","author":"L Rong","year":"2024","journal-title":"Br J Clin Pharmacol."},{"key":"pone.0333692.ref018","doi-asserted-by":"crossref","first-page":"1169327","DOI":"10.3389\/fphar.2023.1169327","article-title":"Characteristic analysis of adverse reactions of five anti-TNF\u00c9\u2019 agents: A descriptive analysis from WHO-VigiAccess","volume":"14","author":"M Li","year":"2023","journal-title":"Front Pharmacol."},{"issue":"8","key":"pone.0333692.ref019","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/a-1852-5335","article-title":"Adverse event following immunization (AEFI) in children: An analysis of reporting in VigiAccess","volume":"72","author":"D Pandey","year":"2022","journal-title":"Drug Res (Stuttg)."},{"issue":"11","key":"pone.0333692.ref020","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1111\/bcp.14868","article-title":"Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections","volume":"87","author":"R B\u00f6hm","year":"2021","journal-title":"Br J Clin Pharmacol."},{"issue":"6","key":"pone.0333692.ref021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA \u2013 Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"R B\u00f6hm","year":"2016","journal-title":"PLoS One."},{"key":"pone.0333692.ref022","doi-asserted-by":"crossref","first-page":"107382","DOI":"10.1016\/j.eplepsyres.2024.107382","article-title":"An analysis of suicidal and self-injurious behavior reports with antiseizure medications in the FDA adverse event database","volume":"203","author":"MH Porwal","year":"2024","journal-title":"Epilepsy Res."},{"issue":"8","key":"pone.0333692.ref023","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/14740338.2023.2278700","article-title":"Drug-induced hypoglycemia: A disproportionality analysis of the FAERS database","volume":"23","author":"J Li","year":"2024","journal-title":"Expert Opin Drug Saf."},{"issue":"11","key":"pone.0333692.ref024","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s40618-024-02441-z","article-title":"The real-world safety profile of tirzepatide: Pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database","volume":"47","author":"I Caruso","year":"2024","journal-title":"J Endocrinol Invest."},{"issue":"5","key":"pone.0333692.ref025","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in Singapore \u2013 A comparison of three different disproportionality measures","volume":"15","author":"PS Ang","year":"2016","journal-title":"Expert Opin Drug Saf."},{"issue":"6","key":"pone.0333692.ref026","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Y Noguchi","year":"2021","journal-title":"Brief Bioinform."},{"issue":"14","key":"pone.0333692.ref027","article-title":"Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database","volume":"10","author":"J Zhu","year":"2024","journal-title":"Heliyon."},{"issue":"8","key":"pone.0333692.ref028","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1111\/bcp.15869","article-title":"Bioinformatics-guided disproportionality analysis of sevoflurane-induced nephrogenic diabetes insipidus using the FDA adverse event reporting system database","volume":"90","author":"AT Jacob","year":"2024","journal-title":"Br J Clin Pharmacol."},{"issue":"6","key":"pone.0333692.ref029","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"8","key":"pone.0333692.ref030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"KJ Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"pone.0333692.ref031","doi-asserted-by":"crossref","first-page":"1378010","DOI":"10.3389\/fphar.2024.1378010","article-title":"Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): A pharmacovigilance study based on the FAERS database","volume":"15","author":"P Long","year":"2024","journal-title":"Front Pharmacol."},{"issue":"5","key":"pone.0333692.ref032","article-title":"OmicShare tools: A zero-code interactive online platform for biological data analysis and visualization","volume":"3","author":"H Mu","year":"2024","journal-title":"Imeta."},{"issue":"5","key":"pone.0333692.ref033","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ackd.2017.06.004","article-title":"Hyperkalemia and hypokalemia in CKD: Prevalence, risk factors, and clinical outcomes","volume":"24","author":"S Gilligan","year":"2017","journal-title":"Adv Chronic Kidney Dis."},{"issue":"1","key":"pone.0333692.ref034","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/ndt\/gfz285","article-title":"Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild\/moderate versus severe\/end-stage chronic kidney disease: Comparative results from an open-label, Phase 3 study","volume":"36","author":"SD Roger","year":"2021","journal-title":"Nephrol Dial Transplant."},{"issue":"9","key":"pone.0333692.ref035","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/ndt\/gfz150","article-title":"Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: A nationwide study","volume":"35","author":"P Laureati","year":"2020","journal-title":"Nephrol Dial Transplant."},{"issue":"17","key":"pone.0333692.ref036","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/eurheartj\/ehy100","article-title":"Serum potassium and adverse outcomes across the range of kidney function: A CKD Prognosis Consortium meta-analysis","volume":"39","author":"CP Kovesdy","year":"2018","journal-title":"Eur Heart J."},{"issue":"2","key":"pone.0333692.ref037","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10557-018-6783-0","article-title":"Association of abnormal serum potassium levels with arrhythmias and cardiovascular mortality: A systematic review and meta-analysis of observational studies","volume":"32","author":"LK Hoppe","year":"2018","journal-title":"Cardiovasc Drugs Ther."},{"issue":"6","key":"pone.0333692.ref038","article-title":"Severe hyperkalemia requiring hospitalization: Predictors of mortality","volume":"16","author":"JN An","year":"2012","journal-title":"Crit Care."},{"key":"pone.0333692.ref039","doi-asserted-by":"crossref","first-page":"653634","DOI":"10.3389\/fmed.2021.653634","article-title":"Management of chronic hyperkalemia in patients with chronic kidney disease: An old problem with news options","volume":"8","author":"E Morales","year":"2021","journal-title":"Front Med (Lausanne)."},{"issue":"3","key":"pone.0333692.ref040","article-title":"Safety assessment of sodium zirconium cyclosilicate: A FAERS-based disproportionality analysis","volume":"20","author":"Y Yu","year":"2025","journal-title":"PLoS One."}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0333692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:37:33Z","timestamp":1760117853000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0333692"}},"subtitle":[],"editor":[{"given":"Yusuf Oloruntoyin","family":"Ayipo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0333692","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]}}}